

Improve your faculty hiring strategy with scite

Making the right hires for your department can be difficult and time-consuming

Which researchers are reliable? Who is pushing the boundaries and challenging the status quo? Identifying the correct established and emerging experts and engaging with them to join your organization can be time-consuming and difficult.

scite helps you uncover the right researchers and effectively engage them

- Search our unique network of Citation Statements directly by keywords for specific disease areas
- Narrow results by topics, relative amounts of support received, and more
- See which researchers are prolific in that space, find their other publications
- Determine how reliable their work is, and what they say about topics you're interested in
- Tailor your outreach and engagement to potential hires based on what you find

hepatocellular carcinoma treatment

736 results (0.76 seconds)

Hide me understand these results Sort by: Relevance

"...In this study, we also found that the liver function improved substantially after high-intensity focused ultrasound treatment, which was consistent with splenectomy. Li et al.³⁷ reported that the splenic and portal venous flows decreased but hepatic arterial flow and the total oxygen supply increased dramatically after the radiofrequency ablation for hypersplenism, and the resultant increase in hepatic arterial flow may improve liver function and induce liver regeneration. Better liver function will favor the recovery of patients with hepatocellular carcinoma..."

Section: Discussion 👍 mentioning confidence: 90%

"...Many studies have shown that high-intensity focused ultrasound treatment can stimulate the body's immune system and accelerate immune reactions. [Shi, 23](#) High-intensity focused ultrasound ablation of the spleen could preserve the spleen to maintain normal immune functions of the body and reduce the probability of recurrence and metastasis in patients with hepatocellular carcinoma. Theoretically, high-intensity focused ultrasound ablation could not only improve clinical symptoms and the quality of life but also increase the survival rate and prolong the survival time for patients with hepatocellular carcinoma complicated by hypersplenism..."

Section: Discussion 👍 mentioning confidence: 90%

See 1 more Smart Citation

High-Intensity Focused Ultrasound Ablation for Treatment of Hepatocellular Carcinoma and Hypersplenism
Jing Zhu¹, Hai Zhu², Zhenhua Mei³ et al., 2013 *Journal of Ultrasound in Medicine*

Topics 3 More

Cancer research (623) x

Hepatocellular carcino... x

Immunology (245) x

Publication Types 2 Editorial Notice

Clinical Trial (478) x

Randomized Controlled Tri... x

Authors Year Sections 1

Author

<input type="checkbox"/>	Masatoshi Kudo	16
<input type="checkbox"/>	Andrew X Zhu	13
<input type="checkbox"/>	Ching Lung Lai	12
<input type="checkbox"/>	Bruno Daniele	10
<input type="checkbox"/>	Hiromitsu Kumada	9

Masatoshi Kudo 🔔 Set alert 🐦 📘 📧

1,500 Publications 61,648 Citation Statements Received 36,454 Citation Statements Given

How they've been cited

📄 77,005 👍 1,688 👎 59,613 🔗 347

How they cite others

📄 35,400 👍 1,065 👎 35,236 🔗 153

The Lancet 2018 DOI: 10.1016/S0140-6736(18)30207-1 [View full text](#) [Buy / Rent full text](#) 🔔 Set alert 🐦 📘 📧

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial 📄

Masatoshi Kudo¹, Richard S. Finn², Shukai Qin³ et al.

Abstract: Eisai Inc.
[Help me understand this report](#)

Search citation statements

Context, author(s), title etc.

Order By: Relevance

Paper Sections 📄

<input type="checkbox"/>	Introduction	1,253
<input type="checkbox"/>	Diskusi	693
<input type="checkbox"/>	Methods	79

👍 Cited by 69 publications (88 citation statements) 📄 References 31 publications (44 reference statements)

"...In this study, a CONUT score <5, ALBI grade 1, BCLC stage B, and AFP <200 ng/mL were identified as independent factors for OS, using multivariate analysis. Previous studies have reported that ALBI grade, AFP level, and BCLC stage are independent factors for OS in patients with HCC treated with LEN [19, 25], indicating that our results showed good agreement with those of previous reports. The CONUT score has previously been reported as a prognostic factor for patients with HCC treated with hepatic resection [24, 25, 33]..."

Section: Discussion 👍 supporting confidence: 92%

"...Yamashita et al previously reported an MST of 17.6 months in Japanese patients with unresectable HCC treated with LEN in a phase 3, multinational, randomized, non-inferiority trial (REFLECT) [22]. Thus, the therapeutic effect of LEN in our study appears to be similar to that reported previously [19, 22, 25], suggesting that the enrolled subjects and treatment effects in our study are typical..."

Section: Discussion 👍 supporting confidence: 87%

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
Shimizu¹, Kawaguchi¹, Usami² et al., 2020 *Biomarkers*

Join over 150,000 scientists, writers, publishers, librarians and researchers across the world championing reproducible science.

Interested in a demo? Get in touch with us at hi@scite.ai